# EDGAR Filing Document

**Accession Number:** 0001809122
**File Stem:** 0001140361-25-045338
**Filing Date:** 2025-12
**Character Count:** 8610
**Document Hash:** 961b72f77e254343ff5a9d4bad5837eb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-045338.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001140361-25-045338

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91630
- **FILM NUMBER:** 251567463

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KfW
- **CENTRAL INDEX KEY:** 0000821533
- **STANDARD INDUSTRIAL CLASSIFICATION:** FOREIGN GOVERNMENTS [8888]
- **ORGANIZATION NAME:** International Corp Fin
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** PALMENGARTENSTRASSE
- **STREET 2:** 5 - 9
- **CITY:** FRANKFURT AM MAIN
- **STATE:** 2M
- **ZIP:** 60325
- **BUSINESS PHONE:** 496974310

**MAIL ADDRESS:**
- **STREET 1:** PALMENGARTENSTRASSE
- **STREET 2:** 5-9
- **CITY:** FRANKFURT AM MAIN
- **STATE:** 2M
- **ZIP:** 60325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KREDITANSTALT FUER WIEDERAUFBAU
- **DATE OF NAME CHANGE:** 19940826

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 7)**

**CureVac N.V.**

*(Name of Issuer)*

**Common Shares Euros 0.12 par value**

*(Title of Class of Securities)*

**N2451R105**

*(CUSIP Number)*

**Pierre-Emmanuel Perais**<br>Linklaters LLP<br>1290 Avenue of the Americas<br>New York NY 10104<br>1 212 903 9046

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **N2451R105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**KfW** | Name of reporting person<br>**KfW** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares Euros 0.12 par value

**(b) Name of Issuer:**
CureVac N.V.

**(c) Address of Issuer's Principal Executive Offices:**
PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG, 2M, 72076

This Amendment No. 7 to the Schedule 13D (the "Amendment No. 7") amends and supplements the Schedule 13D, as amended by Amendment No. 1, dated as of January 29, 2021 (the "Amendment No. 1"), Amendment No. 2, dated as of October 15, 2021 (the "Amendment No. 2"), Amendment No. 3, dated as of January 13, 2022 (the "Amendment No. 3"), Amendment No. 4, dated as of February 10, 2023 (the "Amendment No. 4"), Amendment No. 5, dated as of February 24, 2023 (the "Amendment No. 5") and Amendment No.6, dated as of August 1, 2025 (the "Amendment No.6"). Except as amended and supplemented by the Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment No.5, Amendment No.6 and this Amendment No.7, the Schedule 13D remains unchanged. 

This amendment is being filed to reflect the completion of KfW's tender of all of its Common Shares in the Exchange Offer (as defined below) and the expected termination of the Shareholders' Agreement dated as of June 16, 2020, by and among KfW, Dievini Hopp BioTech holding GmbH & Co. KG ("dievini") and Dietmar Hopp and as amended by Supplement to the Shareholders' Agreement dated as of August 14, 2020 and by Second Supplement to the Shareholders' Agreement dated as of January 13, 2022 (as amended from time to time, the "Shareholders' Agreement") on or about December 15, 2025.

**Item 4. Purpose of Transaction**

Reference is made to that certain (i) Purchase Agreement by and between BioNTech SE, a European stock corporation (the "Buyer") and the Issuer dated June 12, 2025 (the "'Purchase Agreement") and the exchange offer described therein (the "Exchange Offer") and (ii) termination agreement of the Shareholders' Agreement dated October 29, 2025 by and among, KfW, dievini, Zweite DH Verwaltungs GmbH, 4H invest GmbH, Bohlini Invest GmbH, MH-LT Investments GmbH and certain other parties (the "Termination Agreement"). 

KfW has tendered all of its Common Shares into the Exchange Offer pursuant to that certain Tender and Support Agreement dated July 31, 2025 by and between KfW and the Buyer (the "Tender and Support Agreement"), with respect to the Common Shares held by KfW. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Common Shares held by KfW were accepted for exchange and transferred to the Buyer in a capital increase for the issue of shares in Buyer underlying the American Depository Shares of Buyer offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, KfW no longer beneficially owns, or otherwise holds, any securities of the Issuer. 

KfW expects to receive full consideration to which it is entitled under the Exchange Offer (the "Completion") on or about December 15, 2025. Pursuant to the Termination Agreement, the Shareholders' Agreement will terminate upon the Completion.

The foregoing descriptions of the Purchase Agreement and the Tender and Support Agreement, and the respective transactions contemplated thereby, do not purport to be complete and are qualified in their entirety by reference to such agreements. A copy of the Purchase Agreement, listed as Exhibit 1 hereto, is incorporated by reference to Exhibit 99.1 to the Issuer's Current Report on Form 6-K filed with the SEC on June 16, 2025. A copy of the form of Tender and Support Agreement, listed as Exhibit 2 hereto, is incorporated by reference to Exhibit 2 to KfW's Amendment 6 to Schedule 13D filed with the SEC on August 1, 2025.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** KfW

**Signature:** /s/ Uwe Harms

**Name/Title:** Uwe Harms / Authorised Officer (Prokurist)

**Date:** 12/12/2025